Literature DB >> 27013205

Aβ40 has a subtle effect on Aβ42 protofibril formation, but to a lesser degree than Aβ42 concentration, in Aβ42/Aβ40 mixtures.

Shana E Terrill-Usery1, Benjamin A Colvin1, Richard E Davenport1, Michael R Nichols2.   

Abstract

Recent findings suggest that the senile plaques in Alzheimer's disease may contain soluble amyloid-β peptide (Aβ) fibril precursors along with insoluble fibrils. These soluble Aβ species, including oligomers and protofibrils, have been well-studied in vitro and are formed via non-covalent self-assembly of Aβ monomers. While both 40- and 42-residue forms of Aβ are observed in the human body, the majority of the Aβ aggregation work has been conducted on Aβ42 or Aβ40 separately, with relatively few investigations of mixtures. In order to study the effect of different combinations of Aβ40 and Aβ42 on protofibril formation, mixtures of either dry solid peptide, or purified Aβ40 and Aβ42 monomer solutions were mixed together and protofibril/monomer distributions were quantified. Increases in the Aβ42/Aβ40 ratio increased protofibril formation but the presence of Aβ40 in the mixed Aβ solutions had a significant negative impact on protofibril formation compared to equivalent solutions of pure Aβ42. Protofibril size was less affected, but β-sheet structure increased with protofibrils formed from higher Aβ42/Aβ40 ratio solutions. Direct measurement of Aβ42/Aβ40 ratios by C-terminal-selective ELISA found very little Aβ40 incorporated into protofibrils. The cumulative data emphasizes the critical importance of Aβ42, yet establishes Aβ40 as a regulator of Aβ42 aggregation.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aggregation; Amyloid-beta protein; Light scattering; Protofibrils

Mesh:

Substances:

Year:  2016        PMID: 27013205      PMCID: PMC4841699          DOI: 10.1016/j.abb.2016.03.017

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  52 in total

1.  Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates.

Authors:  D M Walsh; D M Hartley; Y Kusumoto; Y Fezoui; M M Condron; A Lomakin; G B Benedek; D J Selkoe; D B Teplow
Journal:  J Biol Chem       Date:  1999-09-03       Impact factor: 5.157

2.  Biophysical comparison of soluble amyloid-β(1-42) protofibrils, oligomers, and protofilaments.

Authors:  Michael R Nichols; Benjamin A Colvin; Elizabeth A Hood; Geeta S Paranjape; David C Osborn; Shana E Terrill-Usery
Journal:  Biochemistry       Date:  2015-03-24       Impact factor: 3.162

3.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

4.  2015 Alzheimer's disease facts and figures.

Authors: 
Journal:  Alzheimers Dement       Date:  2015-03       Impact factor: 21.566

5.  In vitro preparation of prefibrillar intermediates of amyloid-beta and alpha-synuclein.

Authors:  Hilal A Lashuel; Dolors Grillo-Bosch
Journal:  Methods Mol Biol       Date:  2005

6.  Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate.

Authors:  D M Walsh; A Lomakin; G B Benedek; M M Condron; D B Teplow
Journal:  J Biol Chem       Date:  1997-08-29       Impact factor: 5.157

7.  Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43).

Authors:  S A Gravina; L Ho; C B Eckman; K E Long; L Otvos; L H Younkin; N Suzuki; S G Younkin
Journal:  J Biol Chem       Date:  1995-03-31       Impact factor: 5.157

Review 8.  A beta oligomers - a decade of discovery.

Authors:  Dominic M Walsh; Dennis J Selkoe
Journal:  J Neurochem       Date:  2007-02-05       Impact factor: 5.372

Review 9.  Autophagy, amyloidogenesis and Alzheimer disease.

Authors:  Ralph A Nixon
Journal:  J Cell Sci       Date:  2007-12-01       Impact factor: 5.285

10.  Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution.

Authors:  H LeVine
Journal:  Protein Sci       Date:  1993-03       Impact factor: 6.725

View more
  7 in total

1.  UHPLC-QTOF/MS-based metabolomics investigation for the protective mechanism of Danshen in Alzheimer's disease cell model induced by Aβ1-42.

Authors:  Mingyong Zhang; Yue Liu; Min Liu; Biying Liu; Na Li; Xin Dong; Zhanying Hong; Yifeng Chai
Journal:  Metabolomics       Date:  2019-01-17       Impact factor: 4.290

Review 2.  A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Aβ oligomers from Alzheimer's brain.

Authors:  Shaomin Li; Dennis J Selkoe
Journal:  J Neurochem       Date:  2020-04-05       Impact factor: 5.372

3.  The conformational epitope for a new Aβ42 protofibril-selective antibody partially overlaps with the peptide N-terminal region.

Authors:  Benjamin A Colvin; Victoria A Rogers; Joshua A Kulas; Elizabeth A Ridgway; Fatima S Amtashar; Colin K Combs; Michael R Nichols
Journal:  J Neurochem       Date:  2017-11-22       Impact factor: 5.372

4.  Different soluble aggregates of Aβ42 can give rise to cellular toxicity through different mechanisms.

Authors:  Suman De; David C Wirthensohn; Patrick Flagmeier; Craig Hughes; Francesco A Aprile; Francesco S Ruggeri; Daniel R Whiten; Derya Emin; Zengjie Xia; Juan A Varela; Pietro Sormanni; Franziska Kundel; Tuomas P J Knowles; Christopher M Dobson; Clare Bryant; Michele Vendruscolo; David Klenerman
Journal:  Nat Commun       Date:  2019-04-04       Impact factor: 14.919

5.  Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer's disease progression.

Authors:  Suman De; Daniel R Whiten; Francesco S Ruggeri; Craig Hughes; Margarida Rodrigues; Dimitrios I Sideris; Christopher G Taylor; Francesco A Aprile; Serge Muyldermans; Tuomas P J Knowles; Michele Vendruscolo; Clare Bryant; Kaj Blennow; Ingmar Skoog; Silke Kern; Henrik Zetterberg; David Klenerman
Journal:  Acta Neuropathol Commun       Date:  2019-07-26       Impact factor: 7.801

6.  Tumour necrosis factor induces increased production of extracellular amyloid-β- and α-synuclein-containing aggregates by human Alzheimer's disease neurons.

Authors:  Daniel R Whiten; Philip W Brownjohn; Steven Moore; Suman De; Alessio Strano; Yukun Zuo; Moritz Haneklaus; David Klenerman; Frederick J Livesey
Journal:  Brain Commun       Date:  2020-09-15

Review 7.  Looking at Alzheimer's Disease Pathogenesis from the Nuclear Side.

Authors:  Laura D'Andrea; Ramona Stringhi; Monica Di Luca; Elena Marcello
Journal:  Biomolecules       Date:  2021-08-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.